Circulating plasma galectin-3 predicts new-onset atrial fibrillation in patients after acute myocardial infarction during hospitalization
Open Access
- 3 September 2022
- journal article
- research article
- Published by Springer Nature in BMC Cardiovascular Disorders
- Vol. 22 (1) , 1-7
Abstract
New-onset atrial fibrillation (NOAF) is a common complication in patients with acute myocardial infarction (AMI) during hospitalization. Galectin-3 (Gal-3) is a novel inflammation marker that is significantly associated with AF. The association between post-AMI NOAF and Gal-3 during hospitalization is yet unclear. The present study aimed to investigate the predictive value of plasma Gal-3 for post-AMI NOAF. A total of 217 consecutive patients admitted with AMI were included in this retrospective study. Peripheral venous blood samples were obtained within 24 h after admission and plasma Gal-3 concentrations were measured. Post-AMI NOAF occurred in 18 patients in this study. Patients with NOAF were older (p < 0.001) than those without. A higher level of the peak brain natriuretic peptide (BNP) (p < 0.001) and Gal-3 (p < 0.001) and a lower low-density lipoprotein cholesterol level (LDL-C) (p = 0.030), and an estimated glomerular filtration rate (e-GFR) (p = 0.030) were recorded in patients with post-AMI NOAF. Echocardiographic information revealed that patients with NOAF had a significantly decreased left ventricular eject fraction (LVEF) (p < 0.001) and an increased left atrial diameter (LAD) (p = 0.004) than those without NOAF. The receiver operating characteristic (ROC) curve analysis revealed a significantly higher value of plasma Gal-3 in the diagnosis of NOAF for patients with AMI during hospitalization (area under the curve (p < 0.001), with a sensitivity of 72.22% and a specificity of 72.22%, respectively. Multivariate logistic regression model analysis indicated that age (p = 0.045), plasma Gal-3 (p = 0.018), and LAD (p = 0.014) were independent predictors of post-MI NOAF. Plasma Gal-3 concentration is an independent predictor of post-MI NOAF.Keywords
This publication has 36 references indexed in Scilit:
- Galectin-3 and post-myocardial infarction cardiac remodelingEuropean Journal of Pharmacology, 2015
- Atrial remodeling, fibrosis, and atrial fibrillationTrends in Cardiovascular Medicine, 2015
- Plasma galectin-3 predicts clinical outcomes after catheter ablation in persistent atrial fibrillation patients without structural heart diseaseEP Europace, 2015
- The Association of Serum Galectin‐3 Levels with Atrial Electrical and Structural RemodelingJournal of Cardiovascular Electrophysiology, 2015
- Effects of Persistent Atrial Fibrillation on Serum Galectin-3 LevelsThe American Journal of Cardiology, 2015
- Inflammation and the pathogenesis of atrial fibrillationNature Reviews Cardiology, 2015
- Atrial Fibrillation and Death After Myocardial InfarctionCirculation, 2011
- SYMPOSIUM REVIEW: Lipid microdomains and the regulation of ion channel functionThe Journal of Physiology, 2010
- New-onset atrial fibrillation and acute coronary syndromeExpert Review of Cardiovascular Therapy, 2010
- Atrial fibrillation in acute myocardial infarction: a systematic review of the incidence, clinical features and prognostic implicationsEuropean Heart Journal, 2008